Healing & Tissue Repair Peptides
Peptides researched for tissue repair, wound healing, and recovery acceleration. This category includes BPC-157, TB-500, and other compounds studied for their regenerative properties in tendons, ligaments, gut lining, and soft tissue.
Other Categories
Related Categories
AOD-9604
AOD-9604: HGH fragment for fat loss research. Covers lipolytic mechanism without IGF-1 effects, weight management data, dosing, and GRAS safety status.
BPC-157
BPC-157: Gastric-derived healing peptide guide. Covers tissue repair mechanisms, gut-brain axis effects, tendon and GI healing research, and dosing.
Brimapitide
Brimapitide (AM-111): cell-penetrating JNK inhibitor peptide for sudden hearing loss. Phase 3 HEALOS trial results and intratympanic delivery mechanism.
GHK-Cu
GHK-Cu: Copper tripeptide for skin healing and anti-aging. Covers collagen stimulation, wound repair, hair growth, and topical vs injectable use.
Glepaglutide
Glepaglutide (ZP1848): long-acting GLP-2 analog for short bowel syndrome. Phase 3 data shows significant parenteral support reduction. Twice-weekly dosing.
KPV
KPV (Lys-Pro-Val): alpha-MSH-derived anti-inflammatory tripeptide. Inhibits NF-kB without melanocortin receptors. IBD, gut inflammation, and skin research with dosing data.
Larazotide
Larazotide acetate: zonulin receptor antagonist for celiac disease. Phase 2b/3 results, tight junction regulation, and intestinal permeability reduction.
Linaclotide
Linaclotide: FDA-approved guanylate cyclase-C agonist for IBS-C and chronic constipation. Covers mechanism of action, visceral pain reduction, clinical trial results, and safety profile.
LL-37
LL-37: Human cathelicidin antimicrobial peptide guide. Covers membrane disruption, broad-spectrum antibacterial activity, wound healing, and immunity.
MGF
MGF: Mechano Growth Factor for muscle repair. Covers IGF-1 splice variant mechanism, satellite cell activation, exercise response, and dosing data.
Motixafortide
Motixafortide (APHEXDA): FDA-approved CXCR4 antagonist peptide for stem cell mobilization in multiple myeloma. 92.5% success rate in GENESIS Phase 3 trial.
Nomlabofusp
Nomlabofusp (CTI-1601): TAT-frataxin fusion protein for Friedreich ataxia. Phase 2 complete, BLA planned Q2 2026. First disease-modifying FA therapy.
PEG-MGF
PEG-MGF: PEGylated Mechano Growth Factor with extended half-life. Covers satellite cell activation, muscle regeneration research, and MGF comparison.
Risuteganib
Risuteganib (Luminate/ALG-1001): first-in-class integrin-regulating peptide for dry AMD. Phase 2a showed 48% of patients gained 8+ ETDRS letters vs 7% sham.
Rusfertide
Rusfertide (PTG-300): hepcidin mimetic peptide for polycythemia vera. Phase 3 VERIFY showed 77% response rate. FDA Breakthrough Therapy designation.
TB500
TB-500: Thymosin beta-4 guide for tissue repair and healing. Covers actin regulation, wound healing, cardioprotective research, dosing, and side effects.
Teduglutide
Teduglutide (Gattex/Revestive): FDA-approved GLP-2 analog for short bowel syndrome. Promotes intestinal growth and reduces parenteral nutrition dependence.
Head-to-Head Comparisons
Detailed comparisons between healing & tissue repair peptides covering mechanisms, efficacy, side effects, and research evidence.
Related Articles
Weight Loss Peptides for Beginners: Understanding Your Options in 2026
A beginner-friendly guide to weight loss peptides in 2026, covering GLP-1 agonists, dual and triple agonists, non-GLP-1 alternatives, and how to evaluate the evidence behind each option.
guidePeptides for Physical Performance and Endurance: What the Research Shows
An evidence-based guide to peptides studied for physical performance, endurance, and exercise capacity — including MOTS-c, carnosine, tesamorelin, AOD-9604, cortistatin, and BPC-157.
newsFDA Peptide Regulation in 2026: What Is Banned and What Is Legal
FDA peptide regulation in 2026: which peptides are banned from compounding, which remain legal, and what the changes mean for researchers.
news5 Peptides Under FDA Scrutiny: What You Need to Know
Five research peptides facing FDA scrutiny — BPC-157, Thymosin Alpha-1, AOD-9604, CJC-1295 DAC, and Selank — with current legal status.
newsWhat Peptides Did the FDA Ban? A Complete Regulatory Timeline
Complete list of peptides banned from compounding by the FDA, including Category 2 timelines, reasoning, and researcher implications.
guideMost Popular Therapeutic Peptides in 2026: 15 Ranked by Research Interest
The 15 most popular therapeutic peptides in 2026, ranked by clinical trial activity, search interest, and research community adoption. From semaglutide to BPC-157.
Research Tools
Use our interactive tools to explore healing & tissue repair peptides further.